Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that EGFR inhibitor therapy in lung and head/neck cancer patients was associated with acneiform eruptions and severe skin dryness, which rarely necessitate discontinuation of treatment and can be managed symptomatically.

This review discusses cutaneous adverse effects of psychotropic medications and reports no new findings, emphasizing the importance of psychiatrists being aware of these potential skin reactions.

This chapter reviews the skin side effects associated with targeted cancer therapies and emphasizes the importance of collaboration between oncologists and dermatologists without reporting new results.

This article discusses common dermatologic side effects of psychopharmacologic agents such as eruptions, urticaria, and photosensitivity, but it reports no new research findings.

This letter highlights that levonorgestrel intrauterine devices may lead to fewer systemic side effects, like acne, compared to its oral administration due to lower systemic levels of progestogens.

This article reviews the cutaneous side effects of immune checkpoint inhibitors and targeted therapies for skin cancers, noting that while generally mild, these effects can influence treatment decisions and quality of life, underscoring the need for physicians to be aware of these adverse reactions.

This systematic review and meta-analysis found that mood stabilizers used for bipolar disorder, such as lithium, valproate, carbamazepine, and lamotrigine, resulted in varying prevalence of dermatologic side effects, with lamotrigine showing the highest rash incidence, while severe reactions were rare.

This review highlights concerns about dermatological side effects linked to rapid weight loss from glucagon-like peptide-1 receptor agonists used for type 2 diabetes and obesity treatment, such as skin laxity, decreased collagen, and hair loss, emphasizing the importance of managing these while retaining metabolic benefits.

This study reported that chemotherapy-induced skin reactions in cancer patients are mostly mild to moderate and manageable with supportive care, suggesting that early dermatologic intervention can improve patient outcomes without interrupting chemotherapy.

This report describes a case where hidradenitis suppurativa developed in a patient receiving lithium, adding to the recognized cutaneous side effects like psoriasis, acneiform lesions, and alopecia.

This research highlights dermatologists' concerns about the widespread use of sports supplements, noting that nutritional supplements associated with muscle-building and appearance enhancement can lead to dermatological issues like acne and alopecia, while potentially containing harmful substances such as undisclosed anabolic steroids.

This review outlines various dermatologic adverse events associated with targeted therapies and immunotherapies, emphasizing the need for collaboration between dermatologists and oncologists to manage these effects effectively; it reports no new clinical findings.

The researchers reported that dermatological side effects from chemotherapy for women's cancers are common and significantly affect quality of life.

In this study, 97% of patients undergoing pegylated interferon alfa2a and ribavirin therapy for chronic hepatitis C experienced one or more skin-related side effects, with hair loss being the most common.

This review discusses skin-related adverse effects from targeted cancer therapies in dermatology but does not provide new clinical results, emphasizing the essential role of dermatologists in managing these toxicities.

This study observed that 21.6% of oncology patients experienced dermatological side effects from anti-cancer drugs, with hair loss and skin pigmentation changes being the most common.

This study reviewed various dermatological conditions associated with oral contraceptive use, highlighting increased pigmentation, decreased sebum production, and changes in hair growth, among other effects.

In this study, a combination of irinotecan and cetuximab showed varied response rates in metastatic colorectal cancer patients, with manageable skin toxicity that improved quality of life when treated collaboratively by oncology and dermatology teams.

This review discusses the use of cyclosporine in dermatological conditions and its associated monitoring needs and potential side effects, but reports no new research results.

In this four-year study, pediatric patients with inoperable plexiform neurofibromas and type 1 neurofibromatosis treated with selumetinib frequently experienced dermatologic side effects, which required tailored management strategies and sometimes led to treatment suspension, potentially affecting tumor regrowth.

This article addresses an unusual side effect of azathioprine but provides no abstract or detailed results, focusing instead on a specific dermatological perspective.

This review describes minoxidil's hair regrowth mechanism and discusses dermatological applications, but reports no new clinical results, emphasizing the need for regular use and addressing allergic reactions.

This study suggests that cutaneous adverse reactions to bortezomib and lenalidomide are more frequent than reported, impacting patients' quality of life and may require dermatological consultation for proper management.

This study observed that oral mTOR inhibitors frequently cause dermatological side effects, such as mouth ulcers and acneiform eruptions, but these rarely require stopping the treatment.

This article discusses a case of delayed onset perforating folliculitis linked to the use of sorafenib, but it reports no new clinical results.

Panitumumab can cause excessive ear hair growth.

In this study, 37.5% of patients with nodal or metastatic cutaneous melanoma treated with immune checkpoint inhibitors developed skin adverse events, primarily low-grade rashes, vitiligo, and other dermatological symptoms, occurring mainly after 10 weeks of treatment.

Sodium valproate can worsen psoriasis-like skin conditions.

This paper presents a case where alopecia was associated with the use of escitalopram and improved after switching to duloxetine, alongside a literature review of antidepressant-related alopecia.

Sorafenib can cause a temporary skin condition that goes away after stopping the drug.